Cardinal Health's stock dips premarket after company swings to a loss
Cardinal Health Inc.'s stock (CAH) slid 1% in premarket trade Tuesday, after the health services company swung to a loss for its fiscal fourth quarter from a profit a year ago. Dublin, Ohio-based Cardinal Health had a loss of $64 million, or 25 cents a share, for the quarter, after income of $138 million, or 50 cents a share, in the year-earlier period. The loss was mostly due to a non-cash, pre-tax goodwill impairment charge of $368 million in the Medical segment. Adjusted per-share earnings came to $1.55, ahead of the $1.49 FactSet consensus. Revenue rose 13% to $53.5 billion from $47.1 billion a year ago, also ahead of the $52.7 billion FactSet consensus. Chief Executive Jason Hollar said fiscal 2023 was an inflection point for the company, which saw growth in the pharmaceutical segment and "significant improvement" in the medical segment. The company is raising its fiscal 2024 guidance and now expects EPS to range from $6.50 to $6.75, up from prior guidance of $6.45 to $6.70. Revenue is expected to grow 10% to 12%. The stock has gained 21% in the year to date, while the S&P 500 has gained 17%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-15-23 0710ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks